قرار إداري رقم (90) لسنة 2019

باعتماد

أثمان خدمات التحاليل المخبرية لدى هيئة الصحة في دبي

المدير العام

بعد الاطلاع على القانون رقم (14) لسنة 2009 بشأن تسعير الخدمات الحكومية في إمارة دبي وتعديلاته،

وعلى القانون رقم (32) لسنة 2015 بشأن الجريدة الرسمية لحكومة دبي،

وعلى القانون رقم (1) لسنة 2016 بشأن النظام المالي لحكومة دبي،

وعلى القانون رقم (6) لسنة 2018 بشأن هيئة الصحة في دبي، ويُشار إليها فيما بعد **بـِ** "**الهيئة**"،

وعلى المرسوم رقم (9) لسنة 2012 باعتماد آلية تسعير خدمات هيئة الصحة في دبي،

وعلى المرسوم رقم (17) لسنة 2018 بشأن إنشاء المؤسسات التابعة لهيئة الصحة في دبي وتحديد اختصاصاتها،

وعلى المرسوم رقم (18) لسنة 2018 بتعيين مُدير عام هيئة الصحة في دبي،

وعلى قرار المجلس التنفيذي رقم (18) لسنة 2018 باعتماد الهيكل التنظيمي لهيئة الصحة في دبي،

وعلى القرار الإداري رقم (148) لسنة 2014 بشأن رسوم الخدمات الصحية،

وعلى القرار الإداري رقم (210) لسنة 2018 بشأن تسعير التحاليل المخبرية في مختبرات الهيئة وبناءً على موافقة دائرة المالية لحكومة دبي بموجب كتابها المؤرخ في 2018/11/6، على تطبيق الأسعار الجديدة لخدمات التحاليل المخبرية لدى هيئة الصحة في دبي،

قررنا ما يلي:

اعتماد الأثمان

المادة (1)

تُعتمد بموجب هذا القرار، أثمان خدمات التحاليل المخبرية التي يتم إجراؤها في المختبرات العائدة للهيئة، وفقاً لما هو مبيّن في الجدول المُلحق بهذا القرار.

التكليف بالتنفيذ

المادة (2)

على كافة الوحدات التنظيمية في الهيئة، اتخاذ الإجراءات اللازمة لوضع هذا القرار موضع التنفيذ، كل في مجال اختصاصه.

الإلغاء

المادة (3)

يُلغى القرار الإداري رقم (210) لسنة 2018 بشأن تسعير التحاليل المخبرية في مختبرات الهيئة المشار إليه في الأسانيد، كما يُلغى أي حكم أو قرار يتعارض مع أحكام هذا القرار.

السريان والنشر

المادة (4)

يُعمل بهذا القرار من تاريخ 2018/12/25م، ويُنشر في الجريدة الرسمية.

حميد القطامي

المدير العام

صدر في دبي بتاريخ 4 يوليو 2019م

المـــــــــوافق 1 ذو القعدة 1440هـ

Schedule of Dubai Health Authority Laboratory Test Prices

Sr.	Billing Code / Service Code	Service Description	Proposed Charge
1	81378	HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA−A, −B, −C, and −DRB1	3000
2	81379	HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA−A, −B, and −C)	2000
3	81382	HLA Class II typing, high resolution (ie, alleles or allele groups); 1 locus (eg, HLA−DRB1, −DRB3, −DRB4, −DRB5, −DQB1, −DQA1, −DPB1, or −DPA1), each	2000
4	81251	GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2+1G>A)	500
5	81375	HLA Class II typing, low resolution (eg, antigen equivalents); HLA−DRB1/3/4/5 and −DQB1	1000
6	81374	HLA Class I typing, low resolution (eg, antigen equivalents); 1 antigen equivalent (eg, B*27), each	350

7	81228	Cytogenomic constitutional (genome−wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, Bacterial Artificial Chromosome [BAC] or oligo−based comparative genomic hybridization [CGH] microarray analysis)	4800
8	89240	Unlisted miscellaneous pathology test	310
9	81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader−Willi syndrome and/or Angelman syndrome), methylation analysis	440
10	2003074	SIALIDOSIS	1350
11	2006046	BACTERIAL ANTIGEN (CSF)	0
12	2001446	Combine Pitutary Adrenal Tests,Female	0
13	2001447	Combine Pitutary Adrenal Tests,Female	0
14	2001448	Combine Pitutary Adrenal Tests,Female	0
15	2001443	Combine Pitutary Adrenal Tests,Female	0
16	2001450	Combine Pitutary Adrenal Tests,Male	0

17	2001453	Combine Pitutary Adrenal Tests,Male	0
18	2001454	Combine Pitutary Adrenal Tests,Male	0
19	2001455	Combine Pitutary Adrenal Tests,Male	0
20	3010140	CBU MOLECULAR HLA TYPING	2000
21	3010130	REGISTRATION (CBU)	1000
22	3010110	UNRELATED CORD BLOOD DONATION	0
23	3010135	PROCESSING & CRYOPRESERV OF CBU	8000
24	2004457	FOOD INTOLERANCE TEST	3000 gross = 2400 NET
25	81270-1	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant	800
26	81270-2	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant	1289
27	81270-3	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant	1500
28	81270-4	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene	2363

		analysis, p.Val617Phe (V617F) variant	
29	81315	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative	1156
30	81315-1	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative	605
31	81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons) CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy	1278

		[LGMD] type 2M or 2L), full gene sequence MPZ (myelin protein zero) (eg, Charcot–Marie–Tooth), full gene sequence NEFL (neurofilament, light polypeptide) (eg, Charcot–Marie–Tooth), full gene sequence RET (ret proto–oncogene) (eg, multiple endocrine neoplasia, type 2A and familial medullary thyroid carcinoma), targeted sequence analysis (eg, exons 10, 11, 13–16) SDHB (succinate dehydrogenase complex, subunit B, iron sulfur) (eg, hereditary paraganglioma), full gene sequence TGFBR1 (transforming growth factor, beta receptor 1) (eg, Marfan syndrome), full gene sequence TGFBR2 (transforming growth factor, beta receptor 2) (eg, Marfan syndrome), full gene sequence THRB (thyroid hormone receptor, beta) (eg, thyroid hormone resistance, thyroid hormone beta receptor deficiency), full gene sequence or targeted sequence analysis of >5 exons TP53 (tumor protein 53) (eg, Li–Fraumeni	

		syndrome, tumor samples), full gene sequence or targeted sequence analysis of >5 exons VWF (von Willebrand factor) (eg, von Willebrand disease type 2N), targeted sequence analysis (eg, exons 18−20, 23−25)	
32	New	Chimerism testing	2330
33	New	Neopterin	375
34	New	AMPD1 Gene Mutations	1430
35	New	West−Nile−Virus IgM spec. abs. (quant.)	332
36	New	West−Nile−Virus IgG spec. abs. (qual.)	332
37	New	West−Nile−Virus IgG spec. abs. (quant.)	332
38	New	Polycyctic Liver Disease (PCLD)NGS.	6830
39	2082735	JC Virus PCR,CSF	405
40	2082736	Copper Urine,24 Hrs	125
41	2082737	Citrate Urine,24 Hrs	161
42	2082738	HLA−DQ2/8(Celiac Disease)	530
43	2082739	BRAF V600E Mutation	1513
44	2082740	Slides for second opinion	250
45	2082741	Retina Abs	179
46	2082742	Cholestenol Level	73

47	2082743	Phospholipase A2 Receptor Abs Qual	247
48	2082744	Phospholipase A2 Receptor Abs Quan	247
49	2082745	Cimzia Level & Abs	2021
50	2082746	Neopterin, Urine	339
51	2082747	PEX16/PC Gene	5416
52	2082748	Inhibitor Screening	238
53	2082749	HEV abs. (IgG/immunoblot)	185
54	2082750	HEV abs. (IgM/immunoblot)	185
55	2082751	Myelin Oligodendrocyte Glycoprotien Abs	269
56	2082752	CA 125 Body Fluids	185
57	2082753	Carnitine,Total (Serum)	206
58	2082754	Breast & Ovarian Cancer 1 &2	4380
59	2082755	Zinc Transporter 8 Abs	233
60	2082758	Familial Mutation Testing (one mutation, sequencing)	980
61	2082759	17-OH Pregnenolone, 24 Hrs Urine	364
62	2082760	Mutational Analysis CML(Chronic Myeloid Leukaemia)	1509
63	2090001	Fatty Acid Profile, Comprehensive (C8-C26)	200
64	2090002	Glucopsychosine, Blood Spot	1820
65	2090003	Ceramide Trihexosides and Sulfatides, Urine	2366

66	2090004	Tartrate Resistant Acid Phosphatase (TRAP)	1915
67	2090005	Chitotriosidase	427
68	2090006	M GLUR 5 Receptor Abs,Serum	256
69	2090007	M GLUR 5 Receptor Abs,CSF	176
70	2090008	SOX1 ABS,Serum	206
71	2090009	SOX1 ABS,CSF	126
72	2090010	GABA−B−Receptor 1 ABS,Serum	184
73	2090011	GABA−B−Receptor 1 ABS,CSF	104
74	2090012	Glycine Receptor Abs.IgG,Serum	256
75	2090013	Glycine Receptor Abs.IgG,CSF	176
76	2090014	Galactosemia (GALT) gene	3118
77	2090015	Oxalate ,Plasma	182
78	2090016	Beta−Amyloid 42/40 Ratio, CSF	8498

79	81402-1	Molecular pathology procedure, Level 3 (eg, > 10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon) CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), common variants (eg, D816V, D816Y, D816F) MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I,	980

		K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population	

80	81402-2	Molecular pathology procedure, Level 3 (eg, > 10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon) CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), common variants (eg, D816V, D816Y, D816F) MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I,	1928

		K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population	
81	81403	Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of > 10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ABL1 (c-abl oncogene 1, receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), variants in the kinase domain DAZ/SRY (deleted in azoospermia and sex determining	980

		region Y) (eg, male infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd) GJB1 (gap junction protein, beta 1) (eg, Charcot–Marie–Tooth X–linked), full gene sequence JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence and exon 13 sequence, if performed KRAS (v–Ki–ras2 Kirsten rat sarcoma viral oncogene) (eg, carcinoma), gene analysis, variant(s) in exon 2 MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), exon 10 sequence VHL (von Hippel–Lindau tumor suppressor) (eg, von Hippel–Lindau familial cancer syndrome), deletion/duplication analysis VWF (von Willebrand factor) (eg, von Willebrand disease types 2A, 2B, 2M), targeted sequence analysis (eg, exon 28)	
82	84999–1	Unlisted chemistry procedure	1000
83	84999–2	Unlisted chemistry procedure	1293
84	84999–3	Unlisted chemistry procedure	9000
85	84999–4	Unlisted chemistry procedure	12500

86	86160-1	Complement; antigen, each component	120
87	86160-2	Complement; antigen, each component	210
88	86162-1	Complement; total hemolytic (CH50)	184
89	86162-2	Complement; total hemolytic (CH50)	268
90	82657-1	Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	600
91	82657-2	Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	934
92	87797-1	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism	214
93	87797-2	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism	222